J&J sales near $25B for Q1, with solid oncology, immunology gains

Beth Snyder Bulik

Senior Editor

Johnson & Johnson touted gains in its pharmaceutical business that were driven by oncology and immunology drugs, but it was unexpected gains on Covid-19 vaccine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J sales near $25B for Q1, with solid oncology, immunology gains

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

J&J sales near $25B for Q1, with sol­id on­col­o­gy, im­munol­o­gy gains

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

J&J sales near $25B for Q1, with solid oncology, immunology gains